BRISTOL MYERS SQUIBB
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults
Withdrawn
- Conditions
- Hepatitis C
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03208322
- Locations
- 🇲🇽
Local Institution, Magdalena De Las Salinas, Distrito Federal, Mexico
The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany
Withdrawn
- Conditions
- Melanoma
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03205722
A Retrospective, Observational Study on the Effectiveness of Daclatasvir-Containing Regimens in Patients in KSA, UAE and Qatar
Completed
- Conditions
- Hepatitis C
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 182
- Registration Number
- NCT03205618
- Locations
- 🇸🇦
Local Institution, Riyadh-11211, Saudi Arabia
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Cancer
- Interventions
- Biological: LirilumabBiological: NivolumabBiological: Ipilimumab
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 10
- Registration Number
- NCT03203876
- Locations
- 🇯🇵
Local Institution, Kobe-shi, Hyogo, Japan
Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
- Conditions
- Lymphoma
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 95
- Registration Number
- NCT03200977
- Locations
- 🇺🇸
Bristol-Myers Squibb, Princeton, New Jersey, United States
🇺🇸Center for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin, United States
Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States
Completed
- Conditions
- Melanoma
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 650
- Registration Number
- NCT03199846
- Locations
- 🇺🇸
Local Institution, Morristown, New Jersey, United States
A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese Subjects
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 63
- Registration Number
- NCT03198182
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT03198013
- Locations
- 🇦🇺
Local Institution, Melbourne, Victoria, Australia
A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 691
- Registration Number
- NCT03197779
- Locations
- 🇺🇸
Wcct Global, Llc, Cypress, California, United States
🇺🇸California Clinical Trials Medical Group, Glendale, California, United States
🇺🇸Parexel International - Baltimore Epcu, Baltimore, Maryland, United States
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT03195478
- Locations
- 🇨🇳
Local Institution - 0001, Beijing, Beijing, China
🇨🇳Local Institution - 0012, Guangzhou, Guangdong, China
🇨🇳Local Institution - 0020, XiAn, Shan1xi, China
© Copyright 2025. All Rights Reserved by MedPath